CSIMarket
 
Volitionrx Limited  (VNRX)
Other Ticker:  
 
 
Price: $0.9600 $0.06 6.667%
Day's High: $0.96 Week Perf: -9.43 %
Day's Low: $ 0.89 30 Day Perf: -10.28 %
Volume (M): 126 52 Wk High: $ 2.10
Volume (M$): $ 121 52 Wk Avg: $1.19
Open: $0.89 52 Wk Low: $0.55



 Market Capitalization (Millions $) 75
 Shares Outstanding (Millions) 78
 Employees -
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -34
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 1

Volitionrx Limited
Volitionrx Limited is a medical technology company that focuses on developing blood-based diagnostics for different types of cancer and other diseases. It aims to develop novel tests that can provide early detection and accurate diagnosis, which can help in improving patient outcomes. The company's flagship product is the Nu.Q blood-based diagnostic platform, which utilizes epigenetic biomarkers to detect various types of cancer. Volitionrx Limited is headquartered in Singapore and operates globally to bring its innovative diagnostic solutions to the market.


   Company Address: 1489 West Warm Springs Road Henderson 89014 NV
   Company Phone Number: 650?1351   Stock Exchange / Ticker: NYSEAMER VNRX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Volitionrx Limited

Volitionrx Limited's Stock Skyrockets, but Challenges Loom: A Closer Look at the Company's Financial Results and Future Prospects



Volitionrx Limited, a biomedical company that specializes in blood-based diagnostics, experienced a significant increase in its stock value over the past week and month. However, despite robust revenue growth, the company continues to face challenges. This article delves into Volitionrx Limited's recent financial results and analyzes how these factors may impact the company's future prospects.
Impressive Revenue Growth:
Volitionrx Limited reported a remarkable year-on-year revenue increase of 405.016% to $0.17 million in the most recent fiscal period. This surge indicates a strong demand for the company's blood-based diagnostic solutions. Such exponential revenue growth demonstrates a positive market reception of Volitionrx's products and services.

Volitionrx Limited

VNRX has failed to break-even despite the epic Surge in revenue at the VNRX over the most recent fiscal period

Volitionrx Limited, a leading company in the In Vitro & In Vivo Diagnostic Substances industry, recently reported a significant increase in revenue for the most recent fiscal period. The company's revenue rose by an impressive 444.149% year on year to $0.22 million. However, despite this remarkable revenue growth, the company's deficit has extended to $-0.14.
In comparison to its industry contemporaries, Volitionrx Limited has outpaced its competitors in terms of revenue growth. The In Vitro & In Vivo Diagnostic Substances industry as a whole experienced a 12.33% increase in revenue during the same period. This indicates that Volitionrx Limited has been able to capture a larger market share and generate more revenue than its peers.

Volitionrx Limited

Despite Revenue Surge, Volitionrx Limited Still Struggles to Attain Profitability by the End of Fiscal Year 2023

Volitionrx Limited is a biotechnology and pharmaceuticals company that has been making waves in the industry in recent years. While the company has experienced some losses over the last fiscal year, they have also seen significant revenue growth that points towards a promising future. In this article, we will explore Volitionrx Limited's recent financial report and what it means for the company moving forward.
According to the most recent financial report released by Volitionrx Limited, the company saw a loss per share of $-0.15 in the fiscal period ending on March 31, 2023. This represents an increase in loss per share when compared to the previous reporting season, where they reported a loss per share of $-0.13. While an increase in losses may seem concerning, it is important to note that Volitionrx Limited also reported significant revenue growth during this period.






 

Volitionrx Limited's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com